Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Morra

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The American Journal of Emergency Medicine|April 17, 2026
Closing the treatment gap: Identifying current barriers to thrombolysis in acute ischemic stroke within the treatment time windowCinzia Zehnder, Francesco Morra, Christoph Globas, et al.
Oncotarget|April 19, 2017
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cellsFrancesco Morra, Francesco Merolla, Virginia Napolitano, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 22, 2019
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancerFrancesco Morra, Francesco Merolla, Daniela Criscuolo, et al.
Nuclear Medicine Communications|April 26, 2022
18F-FDG-PET/MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapyGiulia Capelli, Cristina Campi, Quoc Riccardo Bao, et al.
Cancers|October 20, 2019
CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCCFrancesco Morra, Francesco Merolla, Ida Picardi, et al.
BMC Cancer|September 25, 2013
Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumorsStefania Staibano, Gennaro Ilardi, Vincenza Leone, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesotheliomaFrancesco Morra, Francesco Merolla, Debora D'Abbiero, et al.
Clinical Neuroradiology|June 10, 2026
Stent Retriever Assisted Endoluminal Reconstruction (STARecon) in Interventional Stroke ManagementValdas Stonys, Francesco Morra, Patrick Thurner, et al.
Cancers|August 7, 2021
Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic StressVirginia Napolitano, Daniela Russo, Francesco Morra, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2016
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugsUmberto Malapelle, Francesco Morra, Gennaro Ilardi, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The American Journal of Emergency Medicine|April 17, 2026
Closing the treatment gap: Identifying current barriers to thrombolysis in acute ischemic stroke within the treatment time windowCinzia Zehnder, Francesco Morra, Christoph Globas, et al.
Oncotarget|April 19, 2017
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cellsFrancesco Morra, Francesco Merolla, Virginia Napolitano, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 22, 2019
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancerFrancesco Morra, Francesco Merolla, Daniela Criscuolo, et al.
Nuclear Medicine Communications|April 26, 2022
18F-FDG-PET/MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapyGiulia Capelli, Cristina Campi, Quoc Riccardo Bao, et al.
Cancers|October 20, 2019
CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCCFrancesco Morra, Francesco Merolla, Ida Picardi, et al.
BMC Cancer|September 25, 2013
Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumorsStefania Staibano, Gennaro Ilardi, Vincenza Leone, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesotheliomaFrancesco Morra, Francesco Merolla, Debora D'Abbiero, et al.
Clinical Neuroradiology|June 10, 2026
Stent Retriever Assisted Endoluminal Reconstruction (STARecon) in Interventional Stroke ManagementValdas Stonys, Francesco Morra, Patrick Thurner, et al.
Cancers|August 7, 2021
Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic StressVirginia Napolitano, Daniela Russo, Francesco Morra, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2016
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugsUmberto Malapelle, Francesco Morra, Gennaro Ilardi, et al.
Pageof 3